M&A Deal Summary

Becton Dickinson Acquires Atto BioScience

On July 1, 2004, Becton Dickinson acquired life science company Atto BioScience for 25M USD

Acquisition Highlights
  • This is Becton Dickinson’s 2nd transaction in the Life Science sector.
  • This is Becton Dickinson’s 9th largest (disclosed) transaction.
  • This is Becton Dickinson’s 4th transaction in the United States.
  • This is Becton Dickinson’s 1st transaction in Maryland.

M&A Deal Summary
Date 2004-07-01
Target Atto BioScience
Sector Life Science
Buyer(s) Becton Dickinson
Deal Type Add-on Acquisition
Deal Value 25M USD

Target

Atto BioScience

Rockville, Maryland, United States
Atto Bioscience, a privately held Maryland-based company, specializes in optical instrumentation, software, and reagents for real-time analysis of interactions taking place in living cells. These products and technologies are targeted at the emerging field of high content cell analysis that is rapidly taking hold in the pharmaceutical, biotechnology, academic, and government research markets.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Becton Dickinson

Franklin Lake, New Jersey, United States
Category Company
Founded 1897
Sector Medical Products
Employees75,000
Revenue 19.4B USD (2023)
DESCRIPTION

Becton Dickinson is a global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. Becton Dickinson was incorporated in 1897 and is headquartered in Franklin Lake, New Jersey.

DEAL STATS #
Overall 4 of 30
Sector (Life Science) 2 of 7
Type (Add-on Acquisition) 4 of 25
State (Maryland) 1 of 1
Country (United States) 4 of 23
Year (2004) 1 of 1
Size (of disclosed) 9 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2000-12-20 Gentest

Woburn, Massachusetts, United States

Gentest Corporation, a developer of specialty reagents for P450 drug metabolism and toxicology, with one of the broadest portfolios in the industry. Gentest products enable pharmaceutical and biotech companies to screen drug candidates, in vitro, for adverse drug-drug interactions and toxicity, including liver toxicity.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2005-07-01 Takara Bio USA Holdings

Mountain View, California, United States

Takara Bio USA Holdings, Inc. is a provider of kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function.

Sell $60M
Mergr

Product

Company

Legal